Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Enriching the design of Alzheimer's disease clinical trials: Application of the polygenic hazard score and composite outcome measures

Alzheimer s & Dementia Translational Research & Clinical Interventions(2020)10.1002/trc2.12071Source: DataRank Database

Enriching the design of Alzheimer's disease clinical trials: Application of the polygenic hazard score and composite outcome measures is a research paper published in Alzheimer s & Dementia Translational Research & Clinical Interventions (2020). On theSindex it has a DataRank of 0. It has been cited 17 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access17 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (13 grants)Impact (FWCI 1.70)OA: goldTopics (66)IDs (PubMed, PMC, OpenAlex)SDGs (3)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (8)

Yuqi Qiu ORCID,Chun Chieh Fan ORCID,Anders M. Dale ORCID,Jingjing Zou ORCID,Brianna Askew

Live enrichment

PubMed:32999917 PMC:PMC7507583 OpenAlex:https://openalex.org/W3088724019

NIA NIH HHS

Grant: U01 AG024904

NIA NIH HHS

Grant: P30 AG062429

NIA NIH HHS

Grant: R01 AG066088

Canadian Institutes of Health Research

Grant: unidentified

unidentified

National Institutes of Health

Grant: 3U19AG010483-26S4

Alzheimer's Disease Cooperative Study

National Institutes of Health

Grant: 5U01NS093334-02

Chronic Traumatic Encephalopathy: Detection, Diagnosis, Course, and Risk Factors

National Institutes of Health

Grant: 1U01AG024904-01

Alzheimers Disease Neuroimaging Initiative

National Institutes of Health

Grant: 1R01AG066088-01

Sex-specific cognitive expression and risk in preclinical Alzheimer's disease

National Institutes of Health

Grant: 1P30AG062429-01

UCSD Alzheimer's Disease Research Centers P30

National Institutes of Health

Grant: 1R01AG051618-01A1

Phase II RCT of High-dose Vitamin D Supplements in Older Adults without Dementia

National Institutes of Health

Grant: 5R01AG066088-04

Sex-specific cognitive expression and risk in preclinical Alzheimer's disease

National Institutes of Health

Grant: 5P30AG062429-03

UCSD Alzheimer's Disease Research Centers P30

National Institutes of Health

Grant: 5R01AG061146-03

A Seamless Phase 2A-B Randomized Double Blind Placebo Controlled Trial to Evaluate the Efficacy and Safety of PQ 912 in Patients with Early Alzheimer's Disease

FWCI

1.70

Citation Percentile

0.8%

Citation Trend

2020

2021

2022

2023

2024

2026

goldLicense: CC BY NC

journalhttps://alz-journals.onlinelibrary.wiley.com/doi/pdf/10.1002/trc2.12071

publisherhttps://alz-journals.onlinelibrary.wiley.com/doi/pdf/10.1002/trc2.12071

publisherhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Ftrc2.12071

publisherhttps://onlinelibrary.wiley.com/doi/pdf/10.1002/trc2.12071

publisherhttps://onlinelibrary.wiley.com/doi/full-xml/10.1002/trc2.12071

Fields of Study

Dementia and Cognitive Impairment ResearchHealth Systems, Economic Evaluations, Quality of LifeAlzheimer's disease research and treatments0302 clinical medicine03 medical and health sciences

Keywords

Clinical Dementia RatingDementiaHazard ratioPercentileCohortMedicineClinical trialNeuroimagingDiseaseAlzheimer's diseaseCognitionPhysical medicine and rehabilitationPsychologyInternal medicineConfidence intervalPsychiatryStatisticsMathematicsOutcomesMild Cognitive ImpairmentClinical Trial DesignPolygenic Hazard ScorePrevention (rcdc)AgingBiological PsychologyNeurodegenerativeAcquired Cognitive Impairment (rcdc)Clinical Research (rcdc)Aging (rcdc)Brain Disorders (rcdc)Dementia (rcdc)32 Biomedical and Clinical Sciences (for-2020)Neurosciences (rcdc)Research ArticlesNeurodegenerative (rcdc)Alzheimer's Disease (rcdc)52 Psychology (for-2020)3209 Neurosciences (for-2020)Neurological5202 Biological Psychology (for-2020)Clinical SciencesClinical Trials and Supportive ActivitiesClinical Trials and Supportive Activities (rcdc)610Clinical ResearchAcquired Cognitive ImpairmentRC346-4293202 Clinical Sciences (for-2020)Biomedical and Clinical SciencesNeurological (hrcs-hc)Prevention4.1 Discovery and preclinical testing of markers and technologies (hrcs-rac)NeurosciencesAlzheimer's Disease Neuroimaging InitiativeRC952-954.6Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD)Brain Disorders4.1 Discovery and preclinical testing of markers and technologiesGeriatricsAlzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD) (rcdc)Neurology. Diseases of the nervous system

Sustainable Development Goals

SDG 3: 3. Good healthSDG 16: 16. Peace & justiceSDG 0: Good health and well-being